Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Clin Pharmacol Ther. 2011 Jun;89(6):793-7. doi: 10.1038/clpt.2011.55. Epub 2011 Apr 13.
Advances in cheminformatics, bioinformatics, and pharmacology in the context of biological systems are now at a point that these tools can be applied to mechanism-based drug safety assessment and prediction. The development of such predictive tools at the US Food and Drug Administration (FDA) will complement ongoing efforts in drug safety that are focused on spontaneous adverse event reporting and active surveillance to monitor drug safety. This effort will require the active collaboration of scientists in the pharmaceutical industry, academe, and the National Institutes of Health, as well as those at the FDA, to reach its full potential. Here, we describe the approaches and goals for the mechanism-based drug safety assessment and prediction program.
在生物系统背景下,化学生物信息学、生物信息学和药理学的进展已经达到了可以将这些工具应用于基于机制的药物安全性评估和预测的地步。美国食品和药物管理局 (FDA) 开发此类预测工具将补充目前侧重于自发不良事件报告和主动监测以监测药物安全性的药物安全性工作。这一努力将需要制药行业、学术界和美国国立卫生研究院的科学家以及 FDA 的积极合作,以充分发挥其潜力。在这里,我们描述了基于机制的药物安全性评估和预测计划的方法和目标。